

From: [redacted]
To: [redacted] (b)(3);10 USC 424; (b)(6)
Subject: [redacted] analysis in progress
Date: 2020/06/11 10:08:00
Priority: Normal
Type: Note

~~Classification: TOP SECRET~~ [redacted]
~~Classified By:~~ [redacted] (b)(3);10 USC 424; (b)(3);50 USC 3024(i); (b)(6)
~~Derived From:~~ [redacted]
~~Declassify On:~~ 20451231
=====

[redacted] (b)(3);10 USC 424; (b)(6)

I thought I'd share what I have before getting too far along, so at least you can get a sense of the length and structure. We get 1 page, with an opening paragraph (authoritative assessment, [redacted] (b)(3);50 USC 3024(i) context) followed by 3 evidence bullets, which I think we agreed are 1) capabilities and objectives, 2) features for SARS-CoV-2, [redacted] (b)(3);50 USC 3024(i)

I took a shot at the opening paragraph and the 2nd bullet, on SARS-CoV-2 features of note. I'll work in your capabilities/objectives material into the 1st bullet (which I think may be our strongest), and in the meantime will start on the 3rd bullet.

Thank you,
[redacted] (b)(3);10 USC 424; (b)(6)

[redacted] (b)(1); (b)(3);50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

The next two pages are withheld in full citing (b)(1) and (b)(3) 10 USC 424 + 50 USC 3024(i) and (b)(6), and are not provided.